Skip to main content

Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial.

Publication ,  Journal Article
McElroy, SL; Kotwal, R; Guerdjikova, AI; Welge, JA; Nelson, EB; Lake, KA; D'Alessio, DA; Keck, PE; Hudson, JI
Published in: J Clin Psychiatry
December 2006

OBJECTIVE: Binge eating disorder (BED) is associated with obesity. Zonisamide is a novel antiepileptic drug associated with weight loss. The purpose of this study was to evaluate zonisa-mide in the treatment of BED associated with obesity. METHOD: In this 16-week, single-center, randomized, double-blind, placebo-controlled, flexible-dose (100-600 mg/day) trial, 60 outpatients with DSM-IV-TR BED received zonisamide (N = 30) or placebo (N = 30). The primary outcome measure was weekly frequency of binge eating episodes. The primary analysis of efficacy was a longitudinal analysis of the intent-to-treat sample, with treatment-by-time interaction as the effect measure. Patients were enrolled from September 5, 2003, through October 1, 2004. RESULTS: Compared with placebo, zonisamide was associated with a significantly greater rate of reduction in binge eating episode frequency (p = .021), body weight (p < .001), BMI (p = .001), and scores on the Clinical Global Impressions-Severity scale (p < .001), Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (p < .001), and Three Factor Eating Questionnaire disinhibition scales (p < .001). Plasma ghrelin concentrations increased with zonisamide but decreased with placebo (p = .001). The mean (SD) zonisamide daily dose at endpoint evaluation was 436 (159) mg/day. Twelve patients (N = 8 receiving zonisamide, N = 4 receiving placebo) discontinued because of adverse events. The most common reasons for discontinuing zonisamide were accidental injury with bone fracture (N = 2), psychological complaints (N = 2), and cognitive complaints (N = 2). CONCLUSION: Zonisamide was efficacious, but not well tolerated, in the short-term treatment of BED associated with obesity. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov identifier NCT00221442.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Psychiatry

DOI

EISSN

1555-2101

Publication Date

December 2006

Volume

67

Issue

12

Start / End Page

1897 / 1906

Location

United States

Related Subject Headings

  • Zonisamide
  • Weight Loss
  • Psychiatry
  • Obesity
  • Middle Aged
  • Male
  • Isoxazoles
  • Humans
  • Female
  • Double-Blind Method
 

Citation

APA
Chicago
ICMJE
MLA
NLM
McElroy, S. L., Kotwal, R., Guerdjikova, A. I., Welge, J. A., Nelson, E. B., Lake, K. A., … Hudson, J. I. (2006). Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry, 67(12), 1897–1906. https://doi.org/10.4088/jcp.v67n1209
McElroy, Susan L., Renu Kotwal, Anna I. Guerdjikova, Jeffrey A. Welge, Erik B. Nelson, Kathleen A. Lake, David A. D’Alessio, Paul E. Keck, and James I. Hudson. “Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial.J Clin Psychiatry 67, no. 12 (December 2006): 1897–1906. https://doi.org/10.4088/jcp.v67n1209.
McElroy SL, Kotwal R, Guerdjikova AI, Welge JA, Nelson EB, Lake KA, et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry. 2006 Dec;67(12):1897–906.
McElroy, Susan L., et al. “Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial.J Clin Psychiatry, vol. 67, no. 12, Dec. 2006, pp. 1897–906. Pubmed, doi:10.4088/jcp.v67n1209.
McElroy SL, Kotwal R, Guerdjikova AI, Welge JA, Nelson EB, Lake KA, D’Alessio DA, Keck PE, Hudson JI. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry. 2006 Dec;67(12):1897–1906.

Published In

J Clin Psychiatry

DOI

EISSN

1555-2101

Publication Date

December 2006

Volume

67

Issue

12

Start / End Page

1897 / 1906

Location

United States

Related Subject Headings

  • Zonisamide
  • Weight Loss
  • Psychiatry
  • Obesity
  • Middle Aged
  • Male
  • Isoxazoles
  • Humans
  • Female
  • Double-Blind Method